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Persistent Sterile Leukocyturia Is Associated With Impaired
Renal Function in Human Immunodeficiency Virus Type 1–Infected
Children Treated With Indinavir
Annemarie M. C. van Rossum, MD, PhD*; Jeanne P. Dieleman, PhD‡; Pieter L. A. Fraaij, MD*;
Karlien Cransberg, MD*; Nico G. Hartwig, MD, PhD*; David M. Burger, PharmD, PhD§;
Inge C. Gyssens, MD, PhD‡;; and Ronald de Groot, MD, PhD*
ABSTRACT. Background. Prolonged administration
of indinavir is associated with the occurrence of a variety
of renal complications in adults. These well-documented
side effects have restricted the use of this potent protease
inhibitor in children.
Design. A prospective study to monitor indinavir-re-
lated nephrotoxicity in a cohort of 30 human immunode-
ficiency virus type 1–infected children treated with indi-
navir.
Methods. Urinary pH, albumin, creatinine, the pres-
ence of erythrocytes, leukocytes, bacteria and crystals,
and culture were analyzed every 3 months for 96 weeks.
Serum creatinine levels were routinely determined at the
same time points. Steady-state pharmacokinetics of indi-
navir were done at week 4 after the initiation of indina-
vir.
Results. The cumulative incidence of persistent ster-
ile leukocyturia (>75 cells/L in at least 2 consecutive
visits) after 96 weeks was 53%. Persistent sterile leuko-
cyturia was frequently associated with a mild increase in
the urine albumin/creatinine ratio and by microscopic
hematuria. The cumulative incidence of serum creatinine
levels >50% above normal was 33% after 96 weeks. Chil-
dren with persistent sterile leukocyturia more frequently
had serum creatinine levels of 50% above normal than
those children without persistent sterile leukocyturia. In
children younger than 5.6 years, persistent sterile leuko-
cyturia was significantly more frequent than in older
children. A higher cumulative incidence of persistent
leukocyturia was found in children with an area under
the curve >19 mg/L*h or a peak serum level of indinavir
>12 mg/L. In 4 children, indinavir was discontinued
because of nephrotoxicity. Subsequently, the serum cre-
atinine levels decreased, the urine albumin/creatinine
ratios returned to zero, and the leukocyturia disappeared
within 3 months.
Conclusions. Children treated with indinavir have a
high cumulative incidence of persistent sterile leukocy-
turia. Children with persistent sterile leukocyturia more
frequently had an increase in serum creatinine levels of
>50% above normal. Younger children have an addi-
tional risk for renal complications. The impairment of
the renal function in these children occurred in the ab-
sence of clinical symptoms of nephrolithiasis. Indinavir-
associated nephrotoxicity must be monitored closely,
especially in children with risk factors such as persistent
sterile leukocyturia, age <5.6 years, an area under the
curve of indinavir >19 mg/L*h, and a Cmax >12 mg/L.
Pediatrics 2002;110(2). URL: http://www.pediatrics.org/
cgi/content/full/110/2/e19; human immunodeficiency virus,
children, indinavir, nephrotoxicity.
ABBREVIATIONS. HIV, human immunodeficiency virus; AUC,
area under plasma-concentration curve; IQR, interquartile range.
Indinavir is a potent human immunodeficiencyvirus (HIV)-protease inhibitor that has been usedsuccessfully in adults in combination with nucle-
oside reverse transcriptase inhibitors to suppress in-
fections by HIV-1. Discontinuation of the antiretro-
viral therapy rapidly results in virologic rebound,
decreased immune function, and the redevelopment
of acquired immune deficiency syndrome-defining
illness. Thus, antiretroviral drugs such as indinavir
need to be continued for many years. This necessi-
tates a careful surveillance for long-term toxicity of
the medication.
The experience with the administration of indina-
vir to HIV-1–infected children has been limited be-
cause of the absence of a pediatric formulation and
the well-documented side-effects of the drug on the
upper and lower urinary tract in adults. Indinavir is
metabolized by the liver, but 20% of a single oral
dose is excreted unchanged in the urine.1 pH-depen-
dent crystallization of indinavir in renal tubuli may
cause renal symptoms such as kidney stones, flank
pain (even without evident stone formation), inter-
stitial nephritis, elevation of the serum creatinine,
dysuria, and asymptomatic urine abnormalities such
as hematuria, leukocyturia, and crystalluria. Indina-
vir crystals may illicit an inflammatory response in
the tubules, leading to sterile leukocyturia and renal
insufficiency.2–7 To minimize renal side effects of
indinavir, an increased fluid intake is advised.8
The incidence of indinavir-associated nephrolithi-
asis in adults varies from 4% to 43%.2,9 Renal com-
plications (including nephrolithiasis) from indinavir
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are found in 0% to 80%10–15 and nephrolithiasis in
0% to 20%10,12–15 of children who have been treated
with this drug.
Renal and urologic symptoms of indinavir crystals
have been correlated with the serum levels of indi-
navir.16 In children, sufficiently high area under the
plasma-concentration curves (AUCs) for indinavir
are required to achieve trough levels13,17 associated
with an optimal virologic response.18–20 The risk of
nephrotoxicity in children might therefore be higher
than in adults.
In contrast to symptomatic nephrolithiasis, other
renal complications such as leukocyturia, micro-
scopic hematuria, and crystalluria usually do not
lead to a decision to discontinue indinavir, although
an association between recurrent severe leukocyturia
and renal damage by indinavir-induced crystalluria
has been reported in adults.6,21
Currently, it is unknown whether and when these
asymptomatic signs of renal damage lead to renal
complications and long-term renal damage. This pro-
spective study was performed to monitor renal and
urinary complications in a cohort of 30 HIV-1–in-
fected children treated with indinavir. We hypothe-
sized that indinavir-related nephrotoxicity might oc-
cur more frequently in children than in adults
because of the higher risk for cellular damage to the
still developing renal system.
METHODS
In 1997, a prospective, open, uncontrolled, multicenter study
was initiated to evaluate the clinical, immunologic, and virologic
response to combination therapy consisting of indinavir, zidovu-
dine, and lamivudine in HIV-1–infected children.15 Children 3
months old and 1 of the following 2 items: a decreased CD4
T-cell count (1 year: 1750/mm3, 1 to 2 years: 1000/mm3, 3 to
6 years: 750/mm3, 6 years: 500/mm3) or a HIV-1 RNA load
5000 copies/mL were included. The follow-up period was 96
weeks after the initiation of indinavir. Two years after the initia-
tion of this multicenter study, a separate study was started in 1 of
the participating centers to analyze additional urinalysis parame-
ters with a follow-up period of 96 weeks.
The Ethics Committee of the University Hospital Rotterdam
approved the study. Patients and their caretakers provided writ-
ten informed consent.
Laboratory Parameters
The routinely analyzed laboratory parameters of the children
included dipstick analysis (Rapignost total screen L, Behring Di-
agnostics Inc, Westwood, MA) for urinary pH (at urine pH values
below 5 solubility of indinavir increases22), erythrocytes, leuko-
cytes, and bacteria at baseline (before the use of indinavir) and
every 3 months thereafter. Routine biochemistry tests included
serum creatinine. Steady-state pharmacokinetics of indinavir (400
mg/m2 every 8 hours) were determined at week 4 after the initi-
ation of indinavir. This procedure was repeated when a dosage
adjustment of indinavir was necessary to normalize the area under
AUC concentration to adult values (20 mg/L*h; range: 10–30
mg/L*h).17
Demographic parameters, indinavir start date and stop date,
indinavir dosing regimens, urinary tract symptoms, concomitant
treatment, HIV-1 RNA, and CD4 T-cell counts were recorded on
structured data collection forms. Nephrolithiasis-related symp-
toms included renal colic, flank pain, the passing of a stone, and
gross hematuria.
Additional laboratory tests were performed in children in-
cluded in 1 center, from March 1999 onwards. Urinary pH was
measured by means of calibrated electrode technique. Urine albu-
min and creatinine were measured to calculate the albumin to
creatinine ratio as an indicator of renal damage. Urine light mi-
croscopy for presence of indinavir crystals under a polarized filter
was performed and urine cultures were performed in patients
with a positive dipstick test or microscopy for bacteria.
Sterile leukocyturia is considered to be caused by damage of
renal tubuli. Therefore, we considered this the principal endpoint
this study. Leukocyturia was defined by the presence of a dipstick
test with 75 cells/L. Persistent sterile leukocyturia was present
when leukocyturia with negative urine cultures was found at at
least 2 consecutive visits, after the start of indinavir. In children
with 150 leukocytes/L at at least 2 visits and a negative urine
culture a renal ultrasound was performed.
Analysis
Cumulative incidences of persistent leukocyturia and serum
creatinine50% above age- and sex-specific normal values23 were
calculated with Kaplan-Meier analysis. The influences of pharma-
cokinetic factors were determined with the log rank test. The
relation between the occurrence of persistent leukocyturia and an
increased creatinine and between persistent leukocyturia and
nephrolithiasis-related symptoms were analyzed using the Fisher
exact test. To describe urine abnormalities associated with leuko-
cyturia, we performed a cross-sectional analysis 12 weeks after the
start of the measurement of the additional urinalysis.
RESULTS
Thirty HIV-1–infected children were enrolled be-
tween April 1997 and April 2000. Fifteen children
were available for additional analyses between
March 1999 and March 2001. The other 15 children
were not available for additional analyses for various
reasons: enrollment in a center different from that
where the additional analyses were performed (n 
8), discontinuation of indinavir (n  6; 5 children
because of virologic failure and 1 because of neph-
rotoxicity), and age 18 years (n  1). Baseline char-
acteristics of the children are presented in Table 1.
A good clinical, immunologic, and virologic re-
sponse was observed in all children who were
treated with indinavir. Most of the children needed
600 mg/m2 of indinavir every 8 hours to obtain an
AUC of indinavir between 10 and 30 mg/L*h. The
median interquartile range (IQR) AUC was 19 (14–
28) mg/L*h with a median (IQR) peak level of 9
(6–12) mg/L. Baseline and follow-up serum creati-
nine and urinalysis data were available from 30 chil-
dren in whom indinavir was initiated.
Cumulative Incidence of Persistent Sterile Leukocyturia
(>2 Times >75 Cells/L)
Eleven (37%) of 30 children developed persistent
sterile leukocyturia (2 times or more 75 leuko-
cytes/L). The cumulative incidence after 96 weeks
was 53% with a mean time to leukocyturia of 74
weeks (95% confidence interval: 61–87 weeks) of
combination therapy containing indinavir (Fig 1A).
The influence of age and sex on the cumulative
incidence of persistent sterile leukocyturia was de-
termined. Children were divided into 2 groups:
younger and older than the median age of 5.6 years.
Figure 1B shows that children younger than 5.6 years
had a significantly higher cumulative incidence of
persistent sterile leukocyturia than children older
than 5.6 years (P  .05). Sex did not influence the
incidence of leukocyturia.
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Cumulative Incidence of a Change of Serum Creatinine
>50% Above Age- and Sex-Specific Normal Values
Six (20%) of 30 children had a change of serum
creatinine 50% above age- and sex-specific normal
values. The cumulative incidence after 96 weeks was
33% with a mean time to creatinine increase of 90
weeks (95% confidence interval: 82–98 weeks) of
combination therapy containing indinavir (Fig 1C).
Relation Between Persistent Sterile Leukocyturia and
an Increase of Serum Creatinine
One (5%) of the 19 children without persistent
sterile leukocyturia had a change in serum creatinine
50% above age- and sex-specific normal values,
whereas 5 (45%) of 11 children with persistent sterile
leukocyturia had a change in serum creatinine 50%
above age- and sex-specific normal values (P  .02).
The median (IQR) time to a creatinine increase
among patients with leukocyturia was 24 (0–48)
weeks.
Relation Between Persistent Sterile Leukocyturia and
Pharmacokinetic Parameters
Children with an AUC0–8 of indinavir higher than
the median AUC of 19 mg/L*h had a significantly
higher cumulative incidence of persistent sterile leu-
kocyturia compared with those with an AUC 19
mg/L*h (P  .05). After 96 weeks 8 (67%) of the 12
children with an AUC 19 mg/L*h had persistent
sterile leukocyturia, in contrast with 2 (13%) of 16 of
the children with an AUC 19 mg/L*h. The cumu-
lative incidences were 79% and 19%, respectively,
after 96 weeks (Fig 1D). Having a maximum concen-
tration (Cmax) of indinavir of 12 (mg/L) was signifi-
cantly (P  .02) associated with the presence of per-
sistent sterile leukocyturia. (Fig 1F). Five (24%) of the
21 children with a Cmax 12 mg/L had persistent
sterile leukocyturia, whereas in 5 (71%) of 7 children
with a Cmax 12 mg/L, this abnormality was ob-
served. No relation was found between Cmin and the
presence of persistent sterile leukocyturia, between
age and AUC of indinavir, and between age and
Cmax.
Relation Between Persistent Sterile Leukocyturia and
Nephrolithiasis-Related Symptoms
Four (19%) of the 21 children without persistent
sterile leukocyturia presented with urologic symp-
toms, whereas 7 (78%) of 9 children with persistent
sterile leukocyturia had symptoms during the fol-
low-up time (P  .003).
Hematuria
Persistent hematuria (2  60 cells/L) was not
detected in any child.
In addition to the standard analyses performed in
the 30 children, urine creatinine, urine albumin,
quantitative pH measurements, and crystalluria
were analyzed in 15 children. At the time of the start
of the additional analyses, these children were using
indinavir for a median of 75 weeks (IQR: 8–77
weeks).
A cross-sectional analysis at week 12 after the start
of the initiation of additional analysis showed that in
these children (median time on indinavir [IQR]: 87
[20–89] weeks) 33% of the patients had a change of
serum creatinine 50% above age- and sex-specific
normal values. In 4 of these 5 patients, an albumin/
creatinine ratio 3.5 g/mmol was observed. In 2 of
these patients, indinavir was discontinued because of
nephrolithiasis on renal ultrasound.
Forty-three percent of the patients had leukocytu-
ria, 21% had microscopic hematuria, 54% had crys-
talluria, and 29% had an albumin/creatinine ratio
3.5 g/mmol. Urine cultures were all negative for
bacteria.
In Fig 2, urine abnormalities associated with leu-
kocyturia at week 12 are presented. An increase of
serum creatinine levels of 50% above age- and sex-
specific normal values, an albumin/creatinine ratio
3.5 g/mmol, and hematuria were observed more
frequently in children with leukocyturia. The median
(IQR) albumin/creatinine ratio of children with and
without persistent leukocyturia was 0.7 (0.6–2.5) and
2.8 (1.2–10.6), respectively. In contrast, indinavir
crystalluria was not detected more frequently in chil-
dren with leukocyturia. The presence of symptoms,
urinary pH 5, and the presence of crystalluria were
not associated with persistent sterile leukocyturia.
TABLE 1. Patient Characteristics
Characteristic
Age (y) Median (range) 5.6 (2.4–9.9)
Male N (%) 15 (50)
Body mass index (kg/m2) Median (IQR) 16 (14–17)
HIV-1 RNA (copies/mL) Median (IQR) 127 500 (18 400–661 000)
CD4 cells (cells/L) Median (IQR) 610 (230–880)
Indinavir regimen
400 mg/m2 tid N (%) 8 (27)
500 mg/m2 tid N (%) 11 (37)
600 mg/m2 tid N (%) 7 (23)
700 mg/m2 tid N (%) 4 (13)
500/100 mg/m2 bid* N (%)
Serum creatinine (mol/L) Median (IQR) 24 (19–38)
Urine
Leukocytes 75 cells/L N (%) 0 (0)
Erythrocytes 60 cells/L N (%) 0 (0)
* Indinavir/ritonavir.
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Fig 1. A, Cumulative incidence of persistent sterile leukocyturia. B, Cumulative incidence of persistent sterile leukocyturia in children
5.6 years (dotted line) and in children 5.6 years. C, Cumulative incidence of children with creatinine increase 50% above age- and
sex-specific normal values. D, Cumulative incidence of persistent sterile leukocyturia in children with AUC of indinavir 19 (dotted line)
or 19 mg/L*h. E, Cumulative incidence of persistent sterile leukocyturia in children with Cmax 12 (dotted line) or 12 mg/L.
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Symptoms of Nephrotoxicity After Discontinuation of
Indinavir Because of Nephrotoxicity
In 4 of 15 children, indinavir was discontinued
because of nephrotoxic symptoms (n  2) or neph-
rolithiasis on renal ultrasound (n  2). In these chil-
dren, serum creatinine (mol/L) levels decreased
from a median (IQR) of 54 (49–75) at the last obser-
vation during the use of indinavir to 39 (28–42) 12
weeks after discontinuation of indinavir (P  .07).
The albumin/creatinine ratio decreased from 16 (9–
44) to 0.7 (0.4–2.1) g/mmol (P  .07). Leukocyturia
disappeared within 3 months after the discontinua-
tion of indinavir. Figure 3 shows the serum creati-
nine levels and the albumin/creatinine ratios of the
4 children that discontinued indinavir because of
nephrotoxicity. Urine albumin/creatinine ratio in-
creases preceded serum creatinine increases and may
therefore may be an early marker of renal impair-
ment.
In 3 other children that discontinued indinavir for
other reasons (virologic failure, n 2, and because of
the poor taste of indinavir, n  1) serum creatinine
levels did not decrease, whereas the albumin/creat-
inine ratio showed a decrease from 3.94 (0.51–11.2) to
0 g/mmol (P  .10).
DISCUSSION
We here present the first study to our knowledge
to monitor nephrotoxicity in HIV-1–infected children
with a prolonged treatment with indinavir. We hy-
pothesized that indinavir-related nephrotoxicity
might occur more frequently in children than in
adults because of the higher risk for cellular damage
to the still developing renal system.
In our study, a cumulative incidence of persistent
sterile leukocyturia (2  75 cells/L) of 53% was
observed after 96 weeks. This persistent sterile leu-
kocyturia was frequently accompanied by a mild
increase of the urine albumin/creatinine ratio and
microscopic hematuria. The cumulative incidence of
an increase in serum creatinine levels 50% above
normal was 35% after 96 weeks. Children with per-
sistent sterile leukocyturia more frequently had an
increase of serum creatinine levels of 50% above
normal (P  .02). This suggests that persistent sterile
leukocyturia is an early indication for the develop-
ment of renal damage.
Recently, Gagnon et al21 found a significant reduc-
tion in the renal function of 3 adults with recurrent
severe leukocyturia. Our data confirm the observa-
tions in adults of Gagnon et al, that reduction of renal
function is associated with recurrent severe leukocy-
turia, but not with isolated hematuria or crystalluria.
Renal damage resulting in leukocyturia and an in-
creased creatinine may be a result of irritation of the
Fig 2. Urinary abnormalities associated with leukocyturia (cross-
sectional week 12) in 15 children included in cohort B.
Fig 3. Urine albumin/creatinine ratio (g/mmol) and creatinine levels (mol/L) during the use of indinavir and after discontinuation of
indinavir in 4 children.
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tubular epithelium. This is supported by the patho-
logic finding of tubulointerstitial nephritis in patients
on therapy with indinavir.4,24,25
The prevalence of persistent leukocyturia in adults
screened on the same nephrotoxicity monitoring pro-
gram was 22% (J. P. Dieleman, personal communi-
cation, September 10, 2001), which is substantially
lower than we observed in children. One might hy-
pothesize that indinavir crystals more easily congest
in the small tubuli of young children which may lead
to a higher incidence of nephrolithiasis. The more
frequent presence of persistent sterile leukocyturia in
younger children confirms this observation. How-
ever, nephrolithiasis was only diagnosed by renal
ultrasound in two asymptomatic children with per-
sistent sterile leukocyturia.26 Renal ultrasounds of
the other children with persistent leukocyturia
showed no nephrolithiasis. Because it is well docu-
mented that the occurrence of indinavir nephrolithi-
asis increases with a poor hydration status and high
environmental temperatures,27 the Dutch climate
with relatively moderate temperatures may contrib-
ute to a lower incidence of nephrolithiasis in our
patients. Persistent leukocyturia might have been
prevented by an increased fluid intake. Because it is
more difficult to achieve a large fluid intake in young
children, a relatively small fluid intake in younger
children may be the cause of the more frequent oc-
currence of persistent sterile leukocyturia in children
younger than 5.6 years (cumulative incidence after 96
weeks: 78%).
We did not observe an association between indi-
navir crystalluria and leukocyturia. Because indina-
vir crystals can develop in the urine canister,28 it is
possible that crystalluria reflects the time lapse be-
tween urine collection and urinalysis.
We observed a higher cumulative incidence of per-
sistent leukocyturia in children with an AUC0–8 of
indinavir of 19 (mg/L*h) and in children with a
peak level of indinavir higher than 12 (mg/L). This is
in accordance with previous publications on the re-
lation between levels of indinavir and urologic com-
plications in adults. An AUC of indinavir 20 (mg/
L*h) is associated with virologic failure.17 This
observation complicates the treatment of HIV-1–in-
fected children with indinavir: to achieve optimal
virologic suppression, an AUC higher than 20 (mg/
L*h) is required, but to avoid persistent leukocyturia,
an AUC 19 (mg/L*h) is needed.
These observations suggest that indinavir may be
less useful in the treatment of HIV-1–infected chil-
dren. However, indinavir is a very potent protease
inhibitor which in combination with nucleoside an-
alogues gives an excellent long-term clinical, viro-
logic and immunologic response in adults and in
children.15,29,30 We therefore propose to monitor
nephrotoxicity very closely in children treated with
indinavir and change therapy only in the case of
overt signs of renal impairment. In this respect, it is
reassuring that the signs of renal impairment are
reversible after discontinuation of indinavir. Serum
creatinine levels decreased in the 4 children with
signs of nephrotoxicity who discontinued indinavir.
The urine albumin/creatinine ratio returned to zero
in all patients. It still remains unclear whether renal
impairment is reversible in all stages of damage or
that a chronic renal insufficiency will develop above
a critical level of cellular damage.
CONCLUSION
Prolonged therapy with indinavir is associated
with a high risk for persistent sterile leukocyturia in
children especially in those younger than 5.6 years.
The presence of sterile leukocyturia is associated
with a significant increase in serum creatinine levels.
A high AUC (19 mg/L*h) and high peak levels
(12 mg/L) of indinavir are associated with the
occurrence of leukocyturia. Therapeutic drug moni-
toring of indinavir serum levels is therefore essential
to estimate the risk of nephrotoxicity. Children with
risk factors for the development of nephrotoxicity,
such as an age 5.6 years, AUC of indinavir 19
mg/L*h, and Cmax 12 mg/L, should be monitored
routinely by means of urinalysis and analysis of se-
rum creatinine levels.
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